Ultromics
Active#13 worldwide · Imaging & medical AIEstimated valuation · Imaging & medical AI · United Kingdom
Develops FDA-cleared AI that analyses routine echocardiography ultrasound images to detect heart failure and other cardiac conditions for hospitals.
Estimated valuation
AI · Imaging & medical AI ranking (worldwide)- Anchor
- Last known equity round: Series C · USD 55M · Jul 2025
An indicative editorial estimate produced by AI, imperfect by nature: neither a financial valuation nor investment advice. Only the market sets a company’s value. Method
Uback rankings
How the AI ranks →| Ranking | Tier | Rank | Edition | Next update |
|---|---|---|---|---|
| Imaging & medical AI · worldwide | Top 25 | #13 | Edition 0 · Oct 2026 | 26 Apr 2027 |
Funding history
| Date | Round | Amount | Type | Investors |
|---|---|---|---|---|
| Jul 2025 | Series C | USD 55M | Equity | L&G, Lightrock, Allegis Capital, GV |
Rounds as cited by Uback’s rankings. Equity, debt and grants are shown separately; only equity rounds count towards the valuation anchor.
Latest news
All funding or secondary sale news →Picked up from the press by Uback’s watch and summarised by Uback, with a link to the original article.
Independent analyses
By industry professionals & analystsIndustry professionals and financial analysts can publish their own analysis of Ultromics as a PDF. It must answer at least one of these four questions, and stick to them:
Analyses are the opinion of their authors, not of Uback. They are checked before publication.
Comparable companies in imaging & medical ai
Full imaging & medical ai ranking →Last updated: Oct 2026Report an error
Uback is a content publisher and an aggregator of non-binding expressions of interest. It provides no investment advice, receives no mandate and takes part in no transaction. Rankings, ranges and brackets are editorial estimates produced by AI, purely indicative.